590 related articles for article (PubMed ID: 29496294)
1. Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
Xiao X; Dong D; He W; Song L; Wang Q; Yue J; Xie L
Gynecol Oncol; 2018 Apr; 149(1):146-154. PubMed ID: 29496294
[TBL] [Abstract][Full Text] [Related]
2. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
Rasmussen M; Lim K; Rambech E; Andersen MH; Svane IM; Andersen O; Jensen LH; Nilbert M; Therkildsen C
Gynecol Oncol; 2021 Sep; 162(3):686-693. PubMed ID: 34275654
[TBL] [Abstract][Full Text] [Related]
3. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy.
Chui MH; Ryan P; Radigan J; Ferguson SE; Pollett A; Aronson M; Semotiuk K; Holter S; Sy K; Kwon JS; Soma A; Singh N; Gallinger S; Shaw P; Arseneau J; Foulkes WD; Gilks CB; Clarke BA
Am J Surg Pathol; 2014 Sep; 38(9):1173-81. PubMed ID: 25025451
[TBL] [Abstract][Full Text] [Related]
4. Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression.
Lin SY; Hang JF; Lin YY; Lai CR; Ho HL; Chou TY
Int J Gynecol Pathol; 2021 Mar; 40(2):148-155. PubMed ID: 32897958
[TBL] [Abstract][Full Text] [Related]
5. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
[TBL] [Abstract][Full Text] [Related]
6. High homogeneity of mismatch repair deficiency in advanced prostate cancer.
Fraune C; Simon R; Höflmayer D; Möller K; Dum D; Büscheck F; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Hinsch A; Burandt E; Clauditz TS; Wilczak W; Sauter G; Steurer S
Virchows Arch; 2020 May; 476(5):745-752. PubMed ID: 31811435
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers.
Hou Y; Nitta H; Parwani AV; Li Z
Hum Pathol; 2019 Apr; 86():108-114. PubMed ID: 30633926
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
[TBL] [Abstract][Full Text] [Related]
10. High homogeneity of MMR deficiency in ovarian cancer.
Fraune C; Rosebrock J; Simon R; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Büscheck F; Höflmayer D; Schmalfeldt B; Müller V; Wölber L; Witzel I; Paluchowski P; Wilke C; Heilenkötter U; von Leffern I; Clauditz TS; Wilczak W; Sauter G; Steurer S; Burandt E
Gynecol Oncol; 2020 Mar; 156(3):669-675. PubMed ID: 31924330
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents.
Bodo S; Colas C; Buhard O; Collura A; Tinat J; Lavoine N; Guilloux A; Chalastanis A; Lafitte P; Coulet F; Buisine MP; Ilencikova D; Ruiz-Ponte C; Kinzel M; Grandjouan S; Brems H; Lejeune S; Blanché H; Wang Q; Caron O; Cabaret O; Svrcek M; Vidaud D; Parfait B; Verloes A; Knappe UJ; Soubrier F; Mortemousque I; Leis A; Auclair-Perrossier J; Frébourg T; Fléjou JF; Entz-Werle N; Leclerc J; Malka D; Cohen-Haguenauer O; Goldberg Y; Gerdes AM; Fedhila F; Mathieu-Dramard M; Hamelin R; Wafaa B; Gauthier-Villars M; Bourdeaut F; Sheridan E; Vasen H; Brugières L; Wimmer K; Muleris M; Duval A;
Gastroenterology; 2015 Oct; 149(4):1017-29.e3. PubMed ID: 26116798
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
[TBL] [Abstract][Full Text] [Related]
14. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
Bregar A; Deshpande A; Grange C; Zi T; Stall J; Hirsch H; Reeves J; Sathyanarayanan S; Growdon WB; Rueda BR
Gynecol Oncol; 2017 Jun; 145(3):446-452. PubMed ID: 28347512
[TBL] [Abstract][Full Text] [Related]
15. Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future.
Yamashita H; Nakayama K; Ishikawa M; Ishibashi T; Nakamura K; Sawada K; Yoshimura Y; Tatsumi N; Kurose S; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31623180
[TBL] [Abstract][Full Text] [Related]
16. Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors.
Salewski I; Henne J; Engster L; Schneider B; Lemcke H; Skorska A; Berlin P; Henze L; Junghanss C; Maletzki C
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206051
[TBL] [Abstract][Full Text] [Related]
17. Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase ε (POLE).
Forgó E; Gomez AJ; Steiner D; Zehnder J; Longacre TA
Histopathology; 2020 Feb; 76(3):366-374. PubMed ID: 31479159
[TBL] [Abstract][Full Text] [Related]
18. Low frequency of mismatch repair deficiency in gallbladder cancer.
Goeppert B; Roessler S; Renner M; Loeffler M; Singer S; Rausch M; Albrecht T; Mehrabi A; Vogel MN; Pathil A; Czink E; Köhler B; Springfeld C; Rupp C; Weiss KH; Schirmacher P; von Knebel Doeberitz M; Kloor M
Diagn Pathol; 2019 May; 14(1):36. PubMed ID: 31068195
[TBL] [Abstract][Full Text] [Related]
19. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
[TBL] [Abstract][Full Text] [Related]
20. Mismatch Repair Deficiency in Endometrial Cancer: Immunohistochemistry Staining and Clinical Implications.
Doghri R; Houcine Y; Boujelbène N; Driss M; Charfi L; Abbes I; Mrad K; Sellami R
Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):678-682. PubMed ID: 31567138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
